Development and validation of a prognostic model for overall survival in chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC) from the phase III PREVAIL clinical trial.

被引：0
|
作者：
Armstrong, Andrew J.
Lin, Ping
Higano, Celestia S.
Sternberg, Cora N.
Sonpavde, Guru
Tombal, Bertrand F.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 06期
关键词：
D O I：
10.1200/JCO.2017.35.6_suppl.138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
138
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Enzalutamide: A Review of Its Use in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Keating, Gillian M.
    DRUGS & AGING, 2015, 32 (03) : 243 - 249
  • [32] Association of alkaline phosphatase with clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): results from COU-AA-302
    Mainwaring, P.
    Yu, E. Y.
    Londhe, A.
    Van Poppel, H.
    Rathkopf, D. E.
    Smith, M. R.
    Souza, P.
    Griffin, T. W.
    Ryan, C. J.
    BJU INTERNATIONAL, 2014, 113 : 21 - 21
  • [33] The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer
    Evans, Christopher P.
    Higano, Celestia S.
    Keane, Thomas
    Andriole, Gerald
    Saad, Fred
    Iversen, Peter
    Miller, Kurt
    Kim, Choung-Soo
    Kimura, Go
    Armstrong, Andrew J.
    Sternberg, Cora N.
    Loriot, Yohann
    de Bono, Johann
    Noonberg, Sarah B.
    Mansbach, Hank
    Bhattacharya, Suman
    Perabo, Frank
    Beer, Tomasz M.
    Tombal, Bertrand
    EUROPEAN UROLOGY, 2016, 70 (04) : 675 - 683
  • [34] Clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis
    Aviles, C. M.
    Azad, A. A.
    Todenhoefer, T.
    Eigl, B. J.
    Kollmannsberger, C.
    Murray, N.
    Chi, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S486 - S487
  • [35] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Tagawa, Scott T.
    Ramaswamy, Krishnan
    Huang, Ahong
    Mardekian, Jack
    Schultz, Neil M.
    Wang, Li
    Sandin, Rickard
    Lechpammer, Stanislav
    George, Daniel J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2021, 24 (04) : 1032 - 1040
  • [36] Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
    Scott T. Tagawa
    Krishnan Ramaswamy
    Ahong Huang
    Jack Mardekian
    Neil M. Schultz
    Li Wang
    Rickard Sandin
    Stanislav Lechpammer
    Daniel J. George
    Prostate Cancer and Prostatic Diseases, 2021, 24 : 1032 - 1040
  • [37] Enzalutamide in Japanese patients with chemotherapy-naive, metastatic castration-resistant prostate cancer: A post-hoc analysis of the placebo-controlled PREVAIL trial
    Kimura, Go
    Yonese, Junji
    Fukagai, Takashi
    Kamba, Tomomi
    Nishimura, Kazuo
    Nozawa, Masahiro
    Mansbach, Hank
    Theeuwes, Ad
    Beer, Tomasz M.
    Tombal, Bertrand
    Ueda, Takeshi
    INTERNATIONAL JOURNAL OF UROLOGY, 2016, 23 (05) : 395 - 403
  • [38] Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC).
    Pond, Gregory Russell
    Templeton, Arnoud J.
    Petrylak, Daniel Peter
    Fandi, Abderrahim
    Tombal, Bertrand F.
    Rosenthal, Mark
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Clinical factors that are prognostic for survival outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223
    Al-Ezzi, E. M. M.
    Alqaisi, H. A.
    Iafolla, M.
    Sridhar, S.
    Sacher, A.
    Fallah-Rad, N.
    Jiang, D. M.
    Catton, C.
    Warde, P.
    Hamilton, R.
    Fleshner, N.
    Zlotta, A.
    Hansen, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S537 - S538
  • [40] Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone
    Ryan, Charles J.
    Kheoh, Thian
    Li, Jinhui
    Molina, Arturo
    De Porre, Peter
    Carles, Joan
    Efstathiou, Eleni
    Kantoff, Philip W.
    Mulders, Peter F. A.
    Saad, Fred
    Chi, Kim N.
    CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : 72 - +
12345